Cargando…

Exploring Metabolomic Patterns in Type 2 Diabetes Mellitus and Response to Glucose-Lowering Medications—Review

The spectrum of information related to precision medicine in diabetes generally includes clinical data, genetics, and omics-based biomarkers that can guide personalized decisions on diabetes care. Given the remarkable progress in patient risk characterization, there is particular interest in using m...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shahisavandi, Mina, Wang, Kan, Ghanbari, Mohsen, Ahmadizar, Fariba
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10379356/ https://www.ncbi.nlm.nih.gov/pubmed/37510368 http://dx.doi.org/10.3390/genes14071464

Ejemplares similares

Mining treatment patterns of glucose-lowering medications for type 2 diabetes in the Netherlands
por: van den Heuvel, Jan Maurik, et al.
Publicado: (2020)

Bi-Directional Interactions between Glucose-Lowering Medications and Gut Microbiome in Patients with Type 2 Diabetes Mellitus: A Systematic Review
por: Li, Ruolin, et al.
Publicado: (2023)

Impaired fasting glucose, type 2 diabetes mellitus, and lifetime risk of cardiovascular disease among women and men: the Rotterdam Study
por: Ahmadizar, Fariba, et al.
Publicado: (2021)

Editorial: Pharmacoepidemiology in Diabetes Mellitus and its Complications: Focus on Response to Medications
por: Mohammadi Jouabadi, Soroush, et al.
Publicado: (2022)

The risk profile of patients with COVID-19 as predictors of lung lesions severity and mortality—Development and validation of a prediction model
por: Rahimi, Ezat, et al.
Publicado: (2022)

Utilization of Pharmacokinetic/Pharmacodynamic Modeling in Pharmacoepidemiological Studies: A Systematic Review on Antiarrhythmic and Glucose-Lowering Medicines
por: Mohammadi Jouabadi, Soroush, et al.
Publicado: (2022)

Metabolomic biomarkers for personalised glucose lowering drugs treatment in type 2 diabetes
por: den Ouden, Henk, et al.
Publicado: (2016)

Proton pump inhibitors are associated with incident type 2 diabetes mellitus in a prospective population‐based cohort study
por: Czarniak, Petra, et al.
Publicado: (2021)

The use of glucose‐lowering medications for the treatment of type 2 diabetes mellitus during pregnancy in the United States
por: Wood, Mollie E., et al.
Publicado: (2021)

Distinctive Metabolomics Patterns Associated With Insulin Resistance and Type 2 Diabetes Mellitus
por: Gu, Xinyun, et al.
Publicado: (2020)

Metabolomics and Cell Therapy in Diabetes Mellitus
por: Larijani, Bagher, et al.
Publicado: (2019)

Cardiorenal Risk Profiles Among Data-Driven Type 2 Diabetes Sub-Phenotypes: A Post-Hoc Analysis of the China Health and Nutrition Survey
por: Gao, Hui, et al.
Publicado: (2022)

The Profile of Glucose Lowering Therapy in Persons with Type 2 Diabetes Mellitus in an Aging Russian Population
por: Malyutina, Sofia, et al.
Publicado: (2022)

Sodium-glucose Cotransporter-2 Inhibitors in Combination with Other Glucose-lowering Agents for the Treatment of Type 2 Diabetes Mellitus
por: Kalra, Sanjay, et al.
Publicado: (2018)

Heart Rate Variability and Incident Type 2 Diabetes in General Population
por: Wang, Kan, et al.
Publicado: (2023)

Interaction Between Non-Insulin Glucose-Lowering Medication and Exercise in Type 2 Diabetes Mellitus – New Findings on SGLT2 Inhibitors
por: Brinkmann, Christian
Publicado: (2021)

Impact of Glucose-Lowering Medications on Cardiovascular and Metabolic Risk in Type 2 Diabetes
por: Patti, Angelo Maria, et al.
Publicado: (2020)

A survey on the factors influencing the pattern of medicine's use: Concerns on irrational use of drugs
por: Soleymani, Fatemeh, et al.
Publicado: (2013)

Comparison of Glucose Lowering Effect of Metformin and Acarbose in Type 2 Diabetes Mellitus: A Meta-Analysis
por: Gu, Shuyan, et al.
Publicado: (2015)

The Relationship between Frequently Used Glucose-Lowering Agents and Gut Microbiota in Type 2 Diabetes Mellitus
por: Lv, You, et al.
Publicado: (2018)

Type 2 Diabetes Clusters Indicate Diabetes Duration Key in Fracture Risk
por: Ghatan, Sam, et al.
Publicado: (2021)

Treatment of Child Gratification Disorder
por: NEMATI, Hamid, et al.
Publicado: (2022)

Sex Differences in Cardiovascular Effectiveness of Newer Glucose‐Lowering Drugs Added to Metformin in Type 2 Diabetes Mellitus
por: Raparelli, Valeria, et al.
Publicado: (2020)

Carbohydrate-last meal pattern lowers postprandial glucose and insulin excursions in type 2 diabetes
por: Shukla, Alpana P, et al.
Publicado: (2017)

The methodology of glucose monitoring in type 2 diabetes mellitus
por: GRIBOVSCHI, MIHAELA
Publicado: (2013)

Integrated biomarker profiling of the metabolome associated with impaired fasting glucose and type 2 diabetes mellitus in large‐scale Chinese patients
por: Long, Jianglan, et al.
Publicado: (2021)

Exploring variables associated with medication non-adherence in patients with type 2 diabetes mellitus
por: Al-Qerem, Walid, et al.
Publicado: (2021)

Metabolomic Signature of Coronary Artery Disease in Type 2 Diabetes Mellitus
por: Stratmann, Bernd, et al.
Publicado: (2017)

Durability of glucose-lowering effect of dulaglutide in patients with type 2 diabetes mellitus: A real-world data study
por: Kim, Hwi Seung, et al.
Publicado: (2022)

Changes in the Prescription of Glucose‐Lowering Medications in Patients With Type 2 Diabetes Mellitus After a Cardiovascular Event: A Call to Action From the DATAFILE Study
por: Fadini, Gian Paolo, et al.
Publicado: (2019)

The healthy beverage index is not associated with insulin resistance, prediabetes and type 2 diabetes risk in the Rotterdam Study
por: Jacobo Cejudo, Maria G., et al.
Publicado: (2023)

Four missense genetic variants in CUBN are associated with higher levels of eGFR in non-diabetes but not in diabetes mellitus or its subtypes: A genetic association study in Europeans
por: Uglebjerg, Nicoline, et al.
Publicado: (2023)

Serological Phenotyping Analysis Uncovers a Unique Metabolomic Pattern Associated With Early Onset of Type 2 Diabetes Mellitus
por: Zhu, Linmin, et al.
Publicado: (2022)

Arterial stiffness in childhood: A predictor for later cardiovascular disease?
por: Ahmadizar, Fariba, et al.
Publicado: (2017)

Exploration of predictive metabolic factors for gestational diabetes mellitus in Japanese women using metabolomic analysis
por: Sakurai, Kenichi, et al.
Publicado: (2018)

Reversibility of brain glucose kinetics in type 2 diabetes mellitus
por: Sanchez-Rangel, Elizabeth, et al.
Publicado: (2022)

Personalized glucose-lowering effect of chiglitazar in type 2 diabetes
por: Huang, Qi, et al.
Publicado: (2023)

Lipid-lowering treatment patterns among patients with type 2 diabetes mellitus with high cardiovascular disease risk
por: Quek, Ruben G W, et al.
Publicado: (2015)

Insulin degludec/insulin aspart in Japanese patients with type 1 diabetes mellitus: Distinct prandial and basal glucose‐lowering effects
por: Haahr, Hanne, et al.
Publicado: (2016)

Sleep characteristics and HbA1c in patients with type 2 diabetes on glucose-lowering medication
por: Tan, Xiao, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_hf67satsqcrn258f69af3hb9gu